<7361> HCH 1904 +3

Consolidation. An article introducing the company was published in the individual investor media "Tickertalk" during the social media era, which discusses the financial results announced on the 14th and the mid-term management plan, etc. However, according to the article, the performance for the full year ending September 2024 reflects that the revenue is 7.165 billion yen (up 10.5% year-on-year and down 8.0% compared to the plan), and EBITDA is 0.759 billion yen (down 7.3% year-on-year and down 9.5% compared to the plan). Given this, the situation of not meeting the plan is considered, and it is said that a revision to a six-year medium and long-term management policy is being made, resulting in a limited impact on the stock price.

<241A> ROXX 1405 +195

Significant rebound. The announcement of the provision of an AI career advisor for job seekers has been positively received. A voice interactive AI career advisor utilizing the latest Realtime API has started to be offered to some job seekers who are users of the non-desk worker job change platform "Z Career." Job seekers can start consultations on job searches anytime with their smartphones and receive job proposals matching their desired conditions quickly. As of the end of July 2024, the cumulative number of subscribers for "Z Career" has surpassed 0.36 million.

<4051> GMO-FG 7510 +1000

Limit up. After the close of trading on the 18th, it was announced that a share buyback would be implemented, which is viewed positively. The upper limit for the total number of shares that can be acquired is 74,000 shares (0.88% of the total issued shares excluding treasury stock) or 0.5 billion yen. The acquisition period is from November 19, 2024, to December 30, 2024, and the method of acquisition is through market purchases on the Tokyo Stock Exchange. The reason for the share buyback is to enable the execution of agile capital policies in response to changes in the management environment, as well as to be part of shareholder returns.

<3967> Eltes 659 +100

Limit up. After the close of trading on the 18th, it was announced that a 20th anniversary commemorative shareholder benefit would be implemented, which is viewed positively. As of the base date of the end of February 2025, shareholders holding over 800 shares will receive a QUO card worth 20,000 yen. There are no restrictions on the holding period. While this 20th anniversary commemorative shareholder benefit is a one-time event, the company positions the return of benefits to shareholders as an important issue and will continue to consider shareholder return measures such as dividends, shareholder benefits, and share buybacks.

＜1444＞ Nisso 2850 +4

Continued rise. Announced a basic agreement to comprehensively partner with Malaysian conglomerate OSK Holdings Berhad in the real estate business, leading to proactive buying in response to this news. With the signing of this basic agreement, the company's group will be able to introduce real estate properties being developed by OSK in Malaysia and Australia in Japan, and since OSK spans multiple industries and is also active in businesses other than real estate, further expansion of international business centered in asia is expected.

＜4576＞ DWTI 97 +30

Hit the limit increase. After the close of trading on the 18th, announced the top-line data results regarding the late-stage Phase II clinical trial of the glaucoma treatment "H-1337," which is seen as favorable. In this trial, effectiveness was shown with a once-daily dosage, and although conjunctival hyperemia was observed regarding safety, most cases were mild and did not lead to discontinuation of medication. Based on these results, it is contemplated that the company will proceed to Phase III clinical trials. There is potential not only as a single agent but also as a combination agent in the future, and the marketability of "H-1337" is anticipated.